Welcome to our dedicated page for Passage Bio SEC filings (Ticker: PASG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech’s disclosures is tough. Passage Bio’s pursuit of one-time AAV gene therapies means its SEC reports are packed with detailed trial data, milestone payments, and cash-runway projections that can span hundreds of pages. Finding when management sold shares or how a new UPenn license changes the balance sheet shouldn’t drain your time.
Stock Titan’s AI turns those dense documents into clear answers. Get real-time alerts the moment a Passage Bio insider trading Form 4 transactions hits EDGAR, see each Passage Bio quarterly earnings report 10-Q filing summarized in plain English, and compare R&D spend across quarters without scrolling line by line. Our platform covers every form—10-K, 10-Q, 8-K, S-3, SC 13G—then distills the implications, risk factors, and segment results so you can act quickly.
- Passage Bio Form 4 insider transactions real-time
- Passage Bio SEC filings explained simply
- Passage Bio earnings report filing analysis
- understanding Passage Bio SEC documents with AI
- Passage Bio executive stock transactions Form 4
- Passage Bio annual report 10-K simplified
- Passage Bio proxy statement executive compensation
- Passage Bio 8-K material events explained
Whether you’re monitoring insider sentiment before pivotal data, tracking partnership economics, or checking the latest cash position, our AI-powered summaries, red-flag highlights, and historical comparisons let you focus on decisions—not documentation. All filings, all the time, already analyzed.
Passage Bio (NASDAQ:PASG) filed a Form 4 showing that 10% owner OrbiMed Advisors, via OrbiMed Private Investments VII, sold 583,657 common shares on 24-26 Jun 2025 at an average price near $0.34.
The disposals cut OrbiMed’s indirect stake from roughly 6.65 million to 6.06 million shares, a reduction of about 8.8% of its holdings, yielding proceeds of approximately $0.20 million. No derivative trades were reported and the Rule 10b5-1 plan box was left unchecked.
- OrbiMed remains a ≥10% beneficial owner.
- The firm disclaims beneficial ownership beyond pecuniary interest.
Sizable sales by a controlling holder can weigh on sentiment despite the modest dollar amount.
OrbiMed Private Investments VII, LP has filed a Form 144 notice indicating their intention to sell 1,076,120 shares of Passage Bio common stock with an aggregate market value of $378,364. The planned sale is scheduled for June 24, 2025, through Themis Trading LLC on the Nasdaq Stock Market.
The securities were originally acquired during Passage Bio's IPO on March 3, 2020. The filing also discloses previous sales by OrbiMed over the past 3 months, totaling 384,626 shares between April 15-24, 2025, with gross proceeds of approximately $128,436.
Key transaction details:
- Total outstanding shares: 62,148,274
- Average selling price of recent transactions: ~$0.33 per share
- Planned sale represents approximately 1.73% of total outstanding shares
Passage Bio announced updated interim data from their Phase 1/2 upliFT-D clinical trial for PBFT02, targeting frontotemporal dementia with GRN gene mutations (FTD-GRN). Key highlights include:
- Dose 1 PBFT02 showed robust and durable increases in CSF progranulin levels through 18 months post-treatment, reaching mean levels of 23.8 ng/mL at 18 months
- Dose 2 (50% of Dose 1) demonstrated promising early results with CSF PGRN increasing from 1.5 to 7.6 ng/mL
- Plasma neurofilament levels showed only 4% increase at 12 months vs. expected 28-29% in untreated patients
- Safety profile: 5 of 8 patients experienced mild to moderate adverse events; 3 patients had serious adverse events including venous sinus thrombosis and pulmonary embolism
The company plans to amend the trial protocol to include prophylactic anticoagulation and expand to Cohorts 3 and 4. Key upcoming milestones include protocol amendment submission (July 2025), manufacturing process feedback (H2 2025), and updated interim data (H1 2026).
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
What is the core focus of Passage Bio, Inc.?
How does Passage Bio use gene therapy in its treatments?
Which disease areas are targeted by Passage Bio's therapies?
What strategic collaborations has Passage Bio established?
How does the company optimize its operational efficiency?
What distinguishes Passage Bio in the competitive gene therapy market?
What role do out-license agreements play in Passage Bio's business model?
How does Passage Bio ensure scientific rigor in its operations?
